Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 36, 2022 - Issue 17
202
Views
4
CrossRef citations to date
0
Altmetric
Short Communications

Chenopodin as an anti-inflammatory compound

, , , , , , , , , & show all
Pages 4429-4432 | Received 04 Jun 2021, Accepted 06 Sep 2021, Published online: 21 Sep 2021
 

Abstract

Chenopodin is an 11S-type globulin purified from Chenopodium quinoa seeds, which can bind carbohydrates and hemagglutinating human erythrocytes. The present study aimed to evaluate the N-terminal structure of the heterodimeric Chenopodin and its effects in models of inflammation. Chenopodin presented two subunits on its structure and has N-terminal homology with other Chenopodin in 92%. Chenopodin decreased paw edema and neutrophil recruitment induced by carrageenan in mice. Concluding, we demonstrated that Chenopodin exhibits in vivo anti-inflammatory activity.

Graphical Abstract

Disclosure statement

The authors declare no conflict of interest.

Additional information

Funding

This work was supported by the National Council for Scientific and Technological Development (CNPq) under number 303307/2018-8; and Minas Gerais Research Foundation (FAPEMIG) under number APQ–03120-16. We are grateful to Coordination for the Improvement of Higher Education Personnel (CAPES – Finance code 001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.